Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7092137> ?p ?o }
Showing triples 1 to 24 of
24
with 100 triples per page.
- Q7092137 subject Q10137627.
- Q7092137 abstract "The Oncotype DX Colon Cancer Assay, developed by Genomic Health, is a genomic test that has been clinically available for patients with newly diagnosed stage II colon cancer, since January 2010. The test is a validated diagnostic assay based on an individual patient’s colon tumor expression of 12 genes, which quantifies the likelihood of recurrence in stage II colon cancer following surgery. The result from the assay is a continuous Recurrence Score® value from 0 to 100 that corresponds to a specific likelihood of colon cancer recurrence 3 years after surgery. A lower score corresponds to a lower risk of recurrence, and a higher score corresponds to a higher risk of recurrence. The Recurrence Score result provides additional information on recurrence risk beyond traditional clinical and pathological characteristics such as tumor stage (T-stage), mismatch repair (MMR) status, number of lymph nodes examined, tumor grade and lymphovascular invasion. The Oncotype DX Colon Cancer Assay has the greatest utility for the stage II colon cancer patients with T3 and MMR proficient tumors.The Oncotype DX assay is a non-invasive test that is performed on a small amount of the tissue removed during surgery, which means no additional invasive procedure is required. After the surgical procedure, the tissue sample is fixed (usually in formalin) and embedded in paraffin so it can be preserved for diagnostic testing. To perform Oncotype DX test, a pathologist will send the tumor block or several thin sections of the tissue sample to Genomic Health. Genomic Health uses a laboratory process known as RT-PCR to measure the expression of the 12-gene panel.".
- Q7092137 wikiPageExternalLink www.genomichealth.com.
- Q7092137 wikiPageExternalLink www.mycoloncancercoach.org.
- Q7092137 wikiPageExternalLink www.oncotypedx.com.
- Q7092137 wikiPageWikiLink Q10137627.
- Q7092137 wikiPageWikiLink Q11053.
- Q7092137 wikiPageWikiLink Q14905499.
- Q7092137 wikiPageWikiLink Q14907908.
- Q7092137 wikiPageWikiLink Q1541222.
- Q7092137 wikiPageWikiLink Q169526.
- Q7092137 wikiPageWikiLink Q170758.
- Q7092137 wikiPageWikiLink Q1752284.
- Q7092137 wikiPageWikiLink Q18023890.
- Q7092137 wikiPageWikiLink Q18027927.
- Q7092137 wikiPageWikiLink Q18029703.
- Q7092137 wikiPageWikiLink Q18029722.
- Q7092137 wikiPageWikiLink Q188874.
- Q7092137 wikiPageWikiLink Q20969939.
- Q7092137 wikiPageWikiLink Q2984243.
- Q7092137 wikiPageWikiLink Q6708283.
- Q7092137 wikiPageWikiLink Q7208.
- Q7092137 comment "The Oncotype DX Colon Cancer Assay, developed by Genomic Health, is a genomic test that has been clinically available for patients with newly diagnosed stage II colon cancer, since January 2010. The test is a validated diagnostic assay based on an individual patient’s colon tumor expression of 12 genes, which quantifies the likelihood of recurrence in stage II colon cancer following surgery.".
- Q7092137 label "Oncotype DX Colon Cancer Assay".